{"title":"规范直接面向消费者的多基因风险评分","authors":"Jacob S. Sherkow, Jin K. Park, Christine Y. Lu","doi":"10.1097/01.ogx.0001008520.24751.6b","DOIUrl":null,"url":null,"abstract":"(Abstracted from JAMA 2023;330:691–692)\n Polygenic risk scores (PGSs) are genome-wide measurements of an individual's genetic propensities or predispositions, and tests have been recently made more accessible and results more available to consumers. With most genetic tests, a healthcare provider helps consumers to interpret results as they relate to medical conditions, but more and more frequently direct-to-consumer PGSs (DTC-PGS) are unregulated.","PeriodicalId":144618,"journal":{"name":"Obstetrical & Gynecological Survey","volume":"95 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Regulating Direct-to-Consumer Polygenic Risk Scores\",\"authors\":\"Jacob S. Sherkow, Jin K. Park, Christine Y. Lu\",\"doi\":\"10.1097/01.ogx.0001008520.24751.6b\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"(Abstracted from JAMA 2023;330:691–692)\\n Polygenic risk scores (PGSs) are genome-wide measurements of an individual's genetic propensities or predispositions, and tests have been recently made more accessible and results more available to consumers. With most genetic tests, a healthcare provider helps consumers to interpret results as they relate to medical conditions, but more and more frequently direct-to-consumer PGSs (DTC-PGS) are unregulated.\",\"PeriodicalId\":144618,\"journal\":{\"name\":\"Obstetrical & Gynecological Survey\",\"volume\":\"95 8\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetrical & Gynecological Survey\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.ogx.0001008520.24751.6b\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrical & Gynecological Survey","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.ogx.0001008520.24751.6b","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
(Abstracted from JAMA 2023;330:691–692)
Polygenic risk scores (PGSs) are genome-wide measurements of an individual's genetic propensities or predispositions, and tests have been recently made more accessible and results more available to consumers. With most genetic tests, a healthcare provider helps consumers to interpret results as they relate to medical conditions, but more and more frequently direct-to-consumer PGSs (DTC-PGS) are unregulated.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
